Ascelia Pharma AB Share Price

Equities

ACE

SE0010573113

Biotechnology & Medical Research

Market Closed - Nasdaq Stockholm 16:29:50 26/04/2024 BST 5-day change 1st Jan Change
11.16 SEK +5.28% Intraday chart for Ascelia Pharma AB -15.33% +231.16%

Financials

Sales 2024 * - Sales 2025 * - Capitalization 377M 34.44M 2.76B
Net income 2024 * -37M -3.38M -271M Net income 2025 * -102M -9.32M -746M EV / Sales 2024 * -
Net cash position 2024 * 18.35M 1.68M 134M Net cash position 2025 * 57M 5.21M 417M EV / Sales 2025 * -
P/E ratio 2024 *
-8.68 x
P/E ratio 2025 *
-4.51 x
Employees 13
Yield 2024 *
-
Yield 2025 *
-
Free-Float 74.72%
More Fundamentals * Assessed data
Dynamic Chart
1 day+5.28%
1 week-15.33%
Current month+21.17%
1 month+14.58%
3 months+28.42%
6 months+273.24%
Current year+231.16%
More quotes
1 week
9.42
Extreme 9.42
13.52
1 month
8.50
Extreme 8.5
14.52
Current year
3.37
Extreme 3.365
14.52
1 year
2.62
Extreme 2.62
17.50
3 years
2.62
Extreme 2.62
39.85
5 years
2.62
Extreme 2.62
66.70
10 years
2.62
Extreme 2.62
66.70
More quotes
Managers TitleAgeSince
Chief Executive Officer 49 31/12/13
Director of Finance/CFO 52 31/12/19
Chief Tech/Sci/R&D Officer 40 31/12/21
Members of the board TitleAgeSince
Chairman 69 31/05/17
Director/Board Member 76 31/12/99
Director/Board Member 59 31/12/16
More insiders
Date Price Change Volume
26/04/24 11.16 +5.28% 118,115
25/04/24 10.6 +9.84% 279,835
24/04/24 9.65 -23.05% 458,993
23/04/24 12.54 -1.72% 186,740
22/04/24 12.76 -3.19% 144,180

Delayed Quote Nasdaq Stockholm, April 26, 2024 at 04:29 pm

More quotes
Ascelia Pharma AB is a Sweden-based pharmaceutical company focused on the development of novel oncology therapies. The Company identifies, acquires and develops differentiated, underappreciated and derisked investigational medicinal drug candidates to make them available to cancer patients. The Company's pipeline includes Mangoral and Oncoral. Mangoral is a medical imaging drug candidate for use in liver Magnetic Resonance Imaging (MRI) for detection and localization of liver metastases in patients with impaired kidneys, which has completed phase II of clinical studies. Oncoral is a tablet formulation of chemotherapeutic agent irinotecan under clinical development for the treatment of gastric cancer. It has completed phase I of clinical studies.
Calendar
More about the company